U.S. Markets open in 16 mins.

DVA Allies Arizona Integrated Physicians

Zacks Equity Research

In order to expand its foothold in Arizona recently, HealthCare Partners LLC, a subsidiary of DaVita HealthCare Partners Inc. (DVA) entered into a merger agreement with the physician owned West-Valley based organization, Arizona Integrated Physicians (:AIP).

As per the deal, AIP which consists of more than 700 physicians who cater to an extensive client base in Arizona will work together with HealthCare Partners to deliver innovative healthcare in Arizona. DaVita has already been operating in Arizona and it intends to widen its presence in the state through the deal.

Over the last 21 years HealthCare Partners of Davita has been engaged in managing and operating medical groups and affiliated physician networks in places like California, Nevada, New Mexico and Florida. It caters to approximately 733,000 managed care patients nationally and is on a spree to associate with other physician and healthcare organizations to expand its clientele base. The addition of AIP is a realization of this goal whereby the latter will accentuate the former’s Arizonian operations.

DaVita announced poor second quarter results for HealthCare Partners in Aug 6, 2013. Thus to recover from the poor numbers in the past, DaVita is focused to strengthen the business developmental front of HealthCare Partners. The above partnership is a reflection of this intention of DaVita.

Among its other partnership endeavors, the association with Myriad RBM in Jun 2013 is worth mentioning. Myriad RBM is a wholly owned subsidiary of a leading molecular diagnostic company, Myriad Genetics Inc. (MYGN). The deal was aimed at performing a protein biomarker discovery research. The objective is to develop and introduce innovative diagnostic tests into the market so that they can be of help in treating dialysis patients   

DaVita currently carries a Zacks Rank #3 (Hold). Other healthcare service providers like Addus Home Corporation (ADUS) with a favorable Zacks Rank #1 (Strong Buy), and Amsurg Corp. (AMSG) with a Zacks Rank #2 (Buy) are worth considering.

Read the Full Research Report on DVARead the Full Research Report on AMSGRead the Full Research Report on MYGNRead the Full Research Report on ADUSZacks Investment Research